8-K current report · filed Aug 5, 2026

BIOCRYST PHARMACEUTICALS INC (BCRX) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1Item 7.01BCRX overview

Short answer

BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026.

BIOCRYST PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026
  • Press release covers financial results and recent corporate developments
  • Conference call and webcast scheduled to discuss Q2 performance
  • Detailed figures and management commentary in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.1 contains the substantive Regulation FD disclosure relevant to investors
  • Item 7.01 signals public distribution of material company information outside periodic reports

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $218.3M, up 34% YoY, with ORLADEYO revenue $158.2M, up 1% YoY
  • Operating profit $98.5M and non-GAAP operating profit $113.2M, supported by licensing revenue
  • FY2026 total revenue guidance raised to $690M-$715M from $635M-$660M, while ORLADEYO guidance remained $625M-$645M
  • Navenibart licensing deal generated $55.7M Q2 revenue, with $275M potential milestones and 18%-30% royalties
  • Pediatric ORLADEYO shipments began August 3, while ALPHA-ORBIT enrollment completion targets Q3 2027 results

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BIOCRYST PHARMACEUTICALS INC 8-K filings

Get the next BCRX 8-K as it lands

Follow BCRX for push alerts, or ask the research agent what this filing means.